Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia

Drug and Alcohol Dependence

Volumn 132, Issue 3, 2013, Pages 674-680

  Krupitsky, Evgeny ^a,b   Zvartau, Edwin ^a,b   Blokhina, Elena ^a,b   Verbitskaya, Elena ^a,b   Tsoy, Marina ^a,b   Wahlgren, Valentina ^a,b   Burakov, Andrey ^a,b   Masalov, Dimitry ^a,b   Romanova, Tatyana N ^a,b   Palatkin, Vladimir ^a,b   Tyurina, Arina ^a,b   Yaroslavtseva, Tatyana ^a,b   Sinha, Rajita ^c   Kosten, Thomas R ^d  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

^c YALE UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trial; Guanfacine; Naltrexone; Opiate dependence; Stress

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE; CANNABIS; COCAINE; GUANFACINE; NALTREXONE; PLACEBO;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; IMPULSIVENESS; INSOMNIA; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PARENT COUNSELING; PERCEIVED STRESS SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RISK FACTOR; RUSSIAN FEDERATION; STRESS; TREATMENT DURATION; URINALYSIS; WITHDRAWAL SYNDROME;

ANIMALIA;

CLINICAL TRIAL; GUANFACINE; NALTREXONE; OPIATE DEPENDENCE; STRESS;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GUANFACINE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RECURRENCE; RUSSIA; YOUNG ADULT;

EID: 84883557160     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.04.021     Document Type: Article

References (30)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Publishing, Inc., Washington, DC. fourth edition. Text Revision.
2. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
3. Bukstein O.G., Head J. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. Expert Opin. Pharmacother. 2012, 13:2207-2213.
4. Carroll K.M., Ball S.A., Nick C., O'Connor P.G., Egan D.A., Frankforter T.L. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence - efficacy of contingency management and significant other involvement. Arch. Gen. Psychiatry 2001, 58:755-761.
5. Cohen S., Kamarck T., Mermelstein R. A global measure of perceived stress. J. Health Soc. Behav. 1983, 24:385-396.
6. De Wet C., Reed L., Glasper A., Moran P., Bear nJ., Gossop M. Benzodiazepine co-dependence exacerbates the opiate withdrawal syndrome. Drug Alcohol Depend. 2004, 76:31-35.
7. Fals-Stewart W., O'Farrell T.J. Behavioral family counseling and naltrexone for male opioid-dependent patients. J. Consult. Clin. Psychol. 2003, 71:432-442.
8. Gish E.C., Miller J.L., Honey B.L., Johnson P.N. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann. Pharmacother. 2010, 44:343-351.
9. Hyman S.M., Fox H., Hong K.I., Doebrick C., Sinha R. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Exp. Clin. Psychopharmacol. 2007, 15:134-143.
10. Hyman S., Hong K.I., Chaplin T.M., Dabre Z., Comegys A.D., Kimmerling A., Sinha R. A stress-coping profile of opioid dependent individuals entering naltrexone treatment: a comparison with healthy controls. Psychol. Addict. Behav. 2009, 23:613-619.
11. Kleber H. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogs Clin. Neurosci. 2007, 9:455-470.
12. Krupitsky E.M., Zvartau E.E., Masalov D.V., Tsoi M.V., Burakov A.M., Egorova V.Y., Didenko T.Y., Romanova T.N., Ivanova E.B., Bespalov A.Y., Verbitskaya E.V., Neznanov N.G., Grinenko A.Y., O'Brien C.P., Woody G.E. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J. Subst. Abuse Treat. 2004, 26:285-294.
13. Krupitsky E.M., Zwartau E.E., Masalov D.V., Tsoy M.V., Burakov A.M., Egorova V.Y., Didenko T.Y., Romanova T.N., Ivanova E.B., Bespalov A.Y., Verbitskaya E.V., Neznanov N.G., Grinenko A.Y., O'Brien C.P., Woody G.E. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J. Subst. Abuse Treat. 2006, 31:319-328.
14. Krupitsky E.M., Blokhina E.A. Long-acting formulations of naltrexone for heroin dependence: a review. Curr. Opin. Psychiatry 2010, 23:210-214.
15. Krupitsky E., Zvartau E., Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr. Psychiatry Rep. 2010, 12:448-453.
16. Krupitsky E., Nunes E., Ling W., Illeperuma A., Gastfriend D., Silverman B. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo controlled multicentre randomized trial. Lancet 2011, 337:1506-1513.
17. Krupitsky E., Zvartau E., Blokhina E., Verbitskaya E., Wahlgren V., Tsoy-Podosenin V., Bushara N., Burakov A., Masalov D., Romanova T., Tyurina A., Palatkin V., Slavina T., Pecoraro A., Woody G.E. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch. Gen. Psychiatry 2012, 69:973-981.
18. Lobmaier P., Gossop M., Waal H., Bramness J. The pharmacological treatment of opioid addiction-a clinical perspective. Eur. J. Clin. Pharmacol. 2010, 66:537-545.
19. Mercer, D., Woody, G.E., 1998. The Penn-VA Addiction Counseling Manual. Available at () (accessed 30.09.05). http://archives.drugabuse.gov/txmanuals/IDCA/IDCA1.html.
20. McLellan A.T., Luborsky L., Cacciola J., Griffith J. New data from the Addiction Severity Index: reliability and validity in three centers. J. Nerv. Ment. Dis. 1985, 173:412-423.
21. Navaline H.A., Snider E.C., Petro C., Tobin D., Metzger D., Alterman A. Preparations for AIDS vaccine trials. An automated version for the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. AIDS Res. Hum. Retroviruses 1994, 10(Suppl. 2):S281-S283.
22. O'Malley S.S., Jaffe A., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B.J. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatry 1992, 49:881-887.
23. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psycholog. Rep. 1962, 10:799-812.
24. Shalev U., Morales M., Hope B.T., Yap J., Shaham Y. Time dependent changes in extinction behavior and stress-induced reinstatement of drug seeking following withdrawal from heroin in rats. Psychopharmacology (Berl.) 2001, 156:98-107.
25. Sinha R., Kimmerling A., Doebrick C., Kosten T.R. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl.) 2007, 190:569-574.
26. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption: Psychological and Biological Methods 1992, Humana Press, Totwa, NJ. R. Litten, J. Allen (Eds.).
27. Sofuoglu M., DeVito E.E., Waters A.J., Carroll K.M. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 2013, 64:452-463.
28. Spielberger C.D., Anton W.D., Bedell J. The nature and treatment of text anxiety. Emotion and Anxiety: New Concepts, Methods and Applications 1976, Erlbaum, Hillsdale, N.J. M. Zuckerman, C.D. Spielberger (Eds.).
29. Stotts A.L., Dodrill C.L., Kosten T.R. Opioid dependence treatment: options in pharmacotherapy. Expert Opin. Pharmacother. 2009, 10:1727-1740.
30. Substance Abuse and Mental Health Services Administration (SAMHSA), Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality (June 2, 2011). The TEDS Report: Substance Abuse Treatment Admissions for Abuse of Benzodiazepines. Rockville, MD.